NASDAQ:TARA Protara Therapeutics Q2 2026 Earnings Report $3.55 -0.15 (-4.05%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$3.55 0.00 (0.00%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Protara Therapeutics EPS ResultsActual EPS-$0.36Consensus EPS -$0.33Beat/MissMissed by -$0.03One Year Ago EPSN/AProtara Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AProtara Therapeutics Announcement DetailsQuarterQ2 2026Date8/11/2026TimeBefore Market OpensConference Call DateTuesday, August 11, 2026Conference Call Time8:00AM ETUpcoming EarningsProtara Therapeutics' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 11, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Protara Therapeutics Earnings HeadlinesProtara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | globenewswire.comProtara’s TARA-002 Moves Into Pivotal Bladder Cancer Trial: What Investors Should WatchAugust 21, 2026 | tipranks.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business UpdateAugust 12, 2026 | markets.businessinsider.comProtara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued PipelineAugust 11, 2026 | seekingalpha.comProtara Therapeutics Announces Key Medical Leadership TransitionJune 29, 2026 | tipranks.comSee More Protara Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Protara Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protara Therapeutics and other key companies, straight to your email. Email Address About Protara TherapeuticsProtara Therapeutics (NASDAQ:TARA) is a clinical-stage biotechnology company focused on developing therapies for cancer and rare diseases. The company’s research programs are designed to address conditions with significant unmet medical needs, including certain solid tumors and lymphatic disorders. Protara’s lead product candidate is TARA-002, an investigational cell-based therapy derived from a proprietary preparation of inactivated Streptococcus pyogenes. The company is evaluating TARA-002 in non-muscle-invasive bladder cancer and lymphatic malformations, a rare condition involving abnormal growth of lymphatic vessels. Protara’s programs remain subject to clinical development and regulatory review, and its product candidates have not been approved for commercial use. The company was formed in 2020 through the combination of ArTara Therapeutics and Proteon Therapeutics and is headquartered in the United States. Protara’s activities are primarily focused on advancing its development pipeline through clinical studies and regulatory processes rather than marketing approved products.View Protara Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in FocusCoreWeave’s Vera Rubin Lead Comes Down to Speed, Power, and ScaleMicron’s New 512GB Memory Module Deepens Its AI Infrastructure AdvantageThese 3 Stocks Are Drawing Insider Buyers for Very Different Reasons Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
